indication directory

AML clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT00658411

Source recordAI-normalized

A Pilot Study of Deferoxamine Before and During Myeloablative Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndromes or Acute Leukemia and Iron Overload

The pilot study sponsored by Dana-Farber Cancer Institute aimed to evaluate the safety and feasibility of deferoxamine in patients with myelodysplastic syndromes or acute leukemia undergoing stem cell transplantation. The study was terminated due to slow patient accrual, indicating potential challenges in recruitment for future studies. The market for iron chelation therapy is significant, particularly in hematological malignancies, but the competitive landscape includes established therapies and emerging novel agents. The limited patient enrollment raises concerns about the viability of further development without robust data supporting efficacy and safety.

AI analysis

Indication: Acute Myeloid Leukemia

Modality: small molecule

Target: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Sponsor: Dana-Farber Cancer Institute

Source URL: ClinicalTrials.gov

Source updated: Apr 09, 2013

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia

View original source fields

Condition raw: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Condition normalized: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Target normalized: Deferoxamine, an iron chelator, targets excess iron in patients with iron overload, particularly in the context of myeloablative allogeneic stem cell transplantation.

Open report

NCT00079378

Source recordAI-normalized

A Phase I Study of Decitabine in Combination With Valproic Acid in Patients With Selected Hematologic Malignancies

The Phase I study of Decitabine in combination with Valproic Acid is sponsored by the National Cancer Institute and focuses on patients with refractory or relapsed acute myeloid leukemia (AML) and previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The combination therapy aims to improve treatment outcomes by leveraging the distinct mechanisms of action of both agents. Given the high unmet medical need in these patient populations, successful outcomes could position this combination as a competitive option in the oncology market. The results may also provide insights into the broader application of epigenetic therapies in hematologic cancers, potentially attracting interest from pharmaceutical companies looking to expand their oncology portfolios.

AI analysis

Indication: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Modality: small molecule

Target: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.

Sponsor: National Cancer Institute (NCI)

Source URL: ClinicalTrials.gov

Source updated: Sep 30, 2013

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

View original source fields

Condition raw: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Untreated Adult Acute Myeloid Leukemia

Condition normalized: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Untreated Adult Acute Myeloid Leukemia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.

Target normalized: Decitabine targets DNA methylation processes, while Valproic Acid inhibits histone deacetylases, potentially enhancing the efficacy of decitabine in treating hematologic malignancies.

Open report

NCT04709458

Source recordAI-normalized

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

Taiga Biotechnologies, Inc. is advancing TBX-2400 through a Phase 1 clinical trial aimed at improving outcomes for patients undergoing allogeneic stem cell transplantation for Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF). The potential to shorten the time to immune reconstitution could position TBX-2400 favorably in a market characterized by high unmet needs in hematologic malignancies. The competitive landscape includes established therapies and emerging candidates targeting similar patient populations. Successful trial outcomes could enhance Taiga's market position and attract partnerships or acquisition interest, given the growing focus on innovative therapies in oncology.

AI analysis

Indication: Myelofibrosis

Modality: protein therapy

Target: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Sponsor: Taiga Biotechnologies, Inc.

Source URL: ClinicalTrials.gov

Source updated: May 03, 2022

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myelogenous Leukemia

View original source fields

Condition raw: Myelofibrosis, Acute Myelogenous Leukemia

Condition normalized: Myelofibrosis, Acute Myelogenous Leukemia

Modality raw: protein therapy

Modality normalized: protein therapy

Target raw: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Target normalized: TBX-2400 is designed to enhance the engraftment of allogeneic hematopoietic stem cells by improving the ability of donor cells to produce blood and immune cells post-transplant without modifying their genetic structure.

Open report

NCT04743115

Source recordAI-normalized

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

BS HH 002.SA is being developed by Shanghai Bensen Pharmaceutical Co., Ltd. for the treatment of relapsed or refractory Acute Myeloid Leukemia (AML) and high-risk Myelodysplastic Syndrome (MDS). The target patient population is significant due to the limited treatment options available for these conditions, suggesting a potentially lucrative market. The study's design includes a dose escalation and cohort expansion, indicating a strategic approach to establishing safety and efficacy. The competitive landscape includes other emerging therapies for AML and MDS, necessitating diligent monitoring of similar clinical trials and market entrants. The trial's current status is 'Not Yet Recruiting,' which may impact timelines for market entry and revenue generation.

AI analysis

Indication: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Modality: small molecule

Target: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Sponsor: Shanghai Bensen Pharmaceutical Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Feb 08, 2021

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome

View original source fields

Condition raw: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Condition normalized: Acute Myeloid Leukemia, Myelodysplastic Syndrome

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Target normalized: Not specified in the provided data; further investigation required to identify the precise molecular or mechanistic target profile of BS HH 002.SA.

Open report

NCT03173248

Source recordAI-normalized

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

AG-120 (ivosidenib) is being evaluated in combination with azacitidine for the treatment of previously untreated acute myeloid leukemia (AML) with an IDH1 mutation. This combination therapy targets a specific patient population that is not suitable for intensive chemotherapy, potentially expanding the market for IDH1 inhibitors in AML treatment. The global AML market is projected to grow significantly, driven by advancements in targeted therapies. Competitive landscape includes other IDH inhibitors and hypomethylating agents, necessitating careful monitoring of clinical outcomes and market positioning. Diligence should focus on the trial's efficacy and safety data, as well as regulatory pathways for approval.

AI analysis

Indication: Newly Diagnosed Acute Myeloid Leukemia (AML)

Modality: small molecule

Target: Isocitrate dehydrogenase 1 (IDH1) mutation

Sponsor: Institut de Recherches Internationales Servier

Source URL: ClinicalTrials.gov

Source updated: Nov 10, 2025

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)

View original source fields

Condition raw: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

Condition normalized: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Isocitrate dehydrogenase 1 (IDH1) mutation

Target normalized: Isocitrate dehydrogenase 1 (IDH1) mutation

Open report

NCT01520558

Source recordAI-normalized

A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

The clinical trial for CNDO-109-Activated Allogeneic Natural Killer Cells targets high-risk acute myeloid leukemia (AML) patients in their first complete remission who are not candidates for stem cell transplantation. Given the high unmet medical need in this patient population, successful outcomes could position Coronado Biosciences favorably in the oncology market, particularly in the immunotherapy segment. The competitive landscape includes other immunotherapeutic approaches for AML, necessitating a thorough assessment of efficacy and safety to differentiate CNDO-109 from existing therapies. Diligence should focus on regulatory pathways and potential partnerships for commercialization, especially considering the trial's non-randomized design and the limited patient enrollment (12 participants).

AI analysis

Indication: Acute Myeloid Leukemia

Modality: protein therapy

Target: CNDO-109-Activated Allogeneic Natural Killer Cells

Sponsor: Coronado Biosciences, Inc.

Source URL: ClinicalTrials.gov

Source updated: Jun 29, 2017

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia

View original source fields

Condition raw: Acute Myeloid Leukemia

Condition normalized: Acute Myeloid Leukemia

Modality raw: protein therapy

Modality normalized: protein therapy

Target raw: CNDO-109-Activated Allogeneic Natural Killer Cells

Target normalized: CNDO-109-Activated Allogeneic Natural Killer Cells

Open report

NCT06128044

Source recordAI-normalized

A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

CB-012, developed by Caribou Biosciences, Inc., is an allogeneic CAR-T cell therapy targeting CLL-1, specifically designed for patients with relapsed or refractory acute myeloid leukemia (AML). The therapy aims to address a significant unmet need in the AML market, particularly for patients who have limited treatment options after multiple lines of therapy. The competitive landscape includes other CAR-T therapies and emerging treatments targeting similar patient populations. However, the unique CRISPR-editing technology may provide a differentiation point in terms of efficacy and safety profile. The termination of this trial due to sponsor decision and pipeline reprioritization raises concerns regarding the asset's future and may indicate a strategic shift within Caribou's portfolio, necessitating further diligence on their remaining assets and overall pipeline strategy.

AI analysis

Indication: Acute Myeloid Leukemia, in Relapse

Modality: cell therapy

Target: C-type lectin-like molecule-1 (CLL-1)

Sponsor: Caribou Biosciences, Inc.

Source URL: ClinicalTrials.gov

Source updated: Jun 11, 2025

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia, in Relapse

View original source fields

Condition raw: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Condition normalized: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: C-type lectin-like molecule-1 (CLL-1)

Target normalized: C-type lectin-like molecule-1 (CLL-1)

Open report

NCT03761914

Source recordAI-normalized

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.

AI analysis

Indication: Acute Myelogenous Leukemia

Modality: monoclonal antibody

Target: galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Sponsor: Sellas Life Sciences Group

Source URL: ClinicalTrials.gov

Source updated: Nov 19, 2024

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myelogenous Leukemia

View original source fields

Condition raw: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer

Condition normalized: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer

Modality raw: monoclonal antibody

Modality normalized: monoclonal antibody

Target raw: galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Target normalized: galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Open report

NCT02310321

Source recordAI-normalized

A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia is a PHASE1 clinical asset sponsored by Astellas Pharma Inc in Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia. SEO and diligence focus: Gilteritinib, Idarubicin, Cytarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Acute Myeloid Leukemia

Modality: small molecule

Target: Gilteritinib, Idarubicin, Cytarabine

Sponsor: Astellas Pharma Inc

Source URL: ClinicalTrials.gov

Source updated: Sep 02, 2025

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia

View original source fields

Condition raw: Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia

Condition normalized: Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Gilteritinib, Idarubicin, Cytarabine

Target normalized: Gilteritinib, Idarubicin, Cytarabine

Open report

NCT05140811

Source recordAI-normalized

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS is a PHASE1 clinical asset sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in Acute Myeloid Leukemia, Myelodysplastic Syndromes. SEO and diligence focus: IMM01, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI analysis

Indication: Acute Myeloid Leukemia

Modality: small molecule

Target: IMM01, Azacitidine

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Source URL: ClinicalTrials.gov

Source updated: May 24, 2023

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Acute Myeloid Leukemia

View original source fields

Condition raw: Acute Myeloid Leukemia, Myelodysplastic Syndromes

Condition normalized: Acute Myeloid Leukemia, Myelodysplastic Syndromes

Modality raw: small molecule

Modality normalized: small molecule

Target raw: IMM01, Azacitidine

Target normalized: IMM01, Azacitidine

Open report